<DOC>
	<DOCNO>NCT00044018</DOCNO>
	<brief_summary>The purpose study select dose regimen CDC-501 provide promising evidence efficacy .</brief_summary>
	<brief_title>CDC-501 Therapy Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Subject must diagnose multiple myeloma ( measurable MProtein serum and/or urine ) , consider disease progression least two cycle treatment relapse treatment . Subject must understand voluntarily sign informed consent document . Subject must receive corticosteroid , chemotherapy , thalidomide , investigational agent , within 21 day baseline ECOG ( Zubrod ) performance status 0 2 . Subject must able adhere study visit schedule protocol requirement . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day baseline . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Revimid</keyword>
	<keyword>CC5013</keyword>
</DOC>